Smad3 Inactivation and MiR-29b Upregulation Mediate the Effect of Carvedilol on Attenuating the Acute Myocardium Infarction-Induced Myocardial Fibrosis in Rat

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Zhu, Jie Ning ^a   Chen, Ren ^a   Fu, Yong Heng ^a   Lin, Qiu Xiong ^a   Huang, Shuai ^a   Guo, Lin Lin ^a   Zhang, Meng Zhen ^a   Deng, Chun Yu ^a   Zou, Xiao ^a   Zhong, Shi Long ^a   Yang, Min ^a   Zhuang, Jian ^a   Yu, Xi Yong ^a   Shan, Zhi Xin ^a,b  

^a GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CARVEDILOL; COL1A1 PROTEIN; COL3A1 PROTEIN; MESSENGER RNA; MICRORNA 29B; PROTEIN; SMAD3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; HEART EJECTION FRACTION; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART MUSCLE INJURY; HEART PROTECTION; HEART VENTRICLE REMODELING; IN VITRO STUDY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; LOW DRUG DOSE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; CARBAZOLES; CARDIOTONIC AGENTS; DOWN-REGULATION; FIBROBLASTS; FIBROSIS; HEART; MALE; MICRORNAS; MYOCARDIAL INFARCTION; MYOCARDIUM; PROPANOLAMINES; RATS; RATS, SPRAGUE-DAWLEY; SMAD3 PROTEIN; UP-REGULATION; VENTRICULAR FUNCTION, LEFT;

EID: 84884546885     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075557     Document Type: Article

References (38)

1. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study group N Engl J Med 334: 1349-1355.
2. Chen-Scarabelli C, Saravolatz L Jr, Murad Y, Shieh WS, Qureshi W, et al. (2012) A critical review of the use of carvedilol in ischemic heart disease. Am J Cardiovasc Drugs 12: 391-401. doi:10.2165/11636090-000000000-00000. PubMed: 23061698.
3. Nanjo S, Yamazaki J, Yoshikawa K, Ishii T, Togane Y, (2006) Carvedilol prevents myocardial fibrosis in hamsters. Int Heart J 47: 607-616. doi:10.1536/ihj.47.607. PubMed: 16960415.
4. Wei S, Chow LT, Sanderson JE, (2000) Effect of carvedilol in comparison with metoprolol on myocardial infarction collagen postinfarction. J Am Coll Cardiol 36: 276-281. doi:10.1016/S0735-1097(00)00671-9. PubMed: 10898446.
5. Bartel DP, (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297. doi:10.1016/S0092-8674(04)00045-5. PubMed: 14744438.
6. Karp X, Ambros V, (2005) Developmental biology: encountering microRNAs in cell fate signaling. Science 310: 1288-1289. doi:10.1126/science.1121566. PubMed: 16311325.
7. Kloosterman WP, Plasterk RH, (2006) The diverse functions of microRNAs in animal development and disease. Dev Cell 11: 441-450. doi:10.1016/j.devcel.2006.09.009. PubMed: 17011485.
8. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, et al. (2007) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103: 18255-18260.
9. Feng Y, Yu X, (2011) Cardinal roles of miRNA in cardiac development and disease. Sci China Life Sci 54: 1113-1120. doi:10.1007/s11431-011-4354-8. PubMed: 22227903.
10. Calin GA, Croce CM, (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866. doi:10.1038/nrc1997. PubMed: 17060945.
11. Liang H, Zhang C, Ban T, Liu Y, Mei L, et al. (2012) A novel reciprocal loop between microRNA-21 and TGFβRIII is involved in cardiac fibrosis. Int J Biochem Cell Biol 44: 2152-2160. doi:10.1016/j.biocel.2012.08.019. PubMed: 22960625.
12. Shan ZX, Lin QX, Fu YH, Deng CY, Zhou ZL, et al. (2009) Upregulated expression of miR-1/miR-206 in a rat model of myocardial infarction. Biochem Biophys Res Commun 381: 597-601. doi:10.1016/j.bbrc.2009.02.097. PubMed: 19245789.
13. Shi B, Guo Y, Wang J, Gao W, (2010) Altered expression of microRNAs in the myocardium of rats with acute myocardial infarction. BMC Cardiovasc Disord 10: 11. doi:10.1186/1471-2261-10-11. PubMed: 20187981.
14. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, et al. (2008) Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105: 13027-13032. doi:10.1073/pnas.0805038105. PubMed: 18723672.
15. Xiao J, Meng XM, Huang XR, Chung AC, Feng YL, et al. (2012) miR-29 inhibits bleomycin-induced pulmonary fibrosis in mice. Mol Ther 20: 1251-1260. doi:10.1038/mt.2012.36. PubMed: 22395530.
16. Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M, (2012) The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics 44: 237-244. doi:10.1152/physiolgenomics.00141.2011. PubMed: 22214600.
17. Dobaczewski M, Chen W, Frangogiannis NG, (2011) Transforming growth factor (TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol 51: 600-606. doi:10.1016/j.yjmcc.2010.10.033. PubMed: 21059352.
18. Fu YH, Lin QX, Li XH, Fei HW, Shan ZX, et al. (2009) A novel rat model of chronic heart failure following myocardial infarction. Methods Find Exp Clin Pharmacol 31: 367-373. PubMed: 19798451.
19. Feuerstein GZ, Ruffolo RR Jr, (1995) Carvedilol, a novel multiple action antihypertensive agent with antioxidant activity and the potential for myocardial and vascular protection. Eur Heart J 16 (Suppl F):: 38-42. doi:10.1093/eurheartj/16.1.38. PubMed: 8521883.
20. Zmijewski JW, Moellering DR, Le Goffe C, Landar A, Ramachandran A, et al. (2005) Oxidized LDL induces mitochondrially associated reactive oxygen/nitrogen species formation in endothelial cells. Am J Physiol Heart Circ Physiol 289: H852-H861. doi:10.1152/ajpheart.00015.2005. PubMed: 15805232.
21. Pfaffl MW, (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45. doi:10.1093/nar/29.9.e45. PubMed: 11328886.
22. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, et al. (2008) 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation 117: 296-329. doi:10.1161/CIRCULATIONAHA.107.188209. PubMed: 18071078.
23. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, et al. (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation 94: 2800-2806. doi:10.1161/01.CIR.94.11.2800. PubMed: 8941105.
24. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, et al. (2002) Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106: 2194-2199. doi:10.1161/01.CIR.0000035653.72855.BF. PubMed: 12390947.
25. Yue TL, Cheng HY, Lysko PG, McKenna PJ, Feuerstein R, et al. (1992) Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263: 92-98. PubMed: 1357162.
26. Zhuang XF, Yin CQ, Wang HY, Sun NL, (2009) Distinctive effects of carvedilol in the non-infarct zone: Remodeling of the ligated rat heart linked to oxidative stress. J Int Med Res 37: 1354-1364. doi:10.1177/147323000903700510. PubMed: 19930840.
27. Wang R, Miura T, Harada N, Kametani R, Shibuya M, et al. (2006) Pleiotropic effects of the beta-adrenoceptor blocker carvedilol on calcium regulation during oxidative stress-induced apoptosis in cardiomyocytes. J Pharmacol Exp Ther 318: 45-52. doi:10.1124/jpet.105.099903. PubMed: 16611853.
28. Zhang JL, Lu JK, Chen D, Cai Q, Li TX, et al. (2009) Myocardial autophagy variation during acute myocardial infarction in rats: The effects of carvedilol. Chin Med J (Engl) 122: 2372-2379. PubMed: 20079142.
29. Senior R, Basu S, Kinsey C, Schaeffer S, Lahiri A, (1999) Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction. Am Heart J 137: 646-652. doi:10.1016/S0002-8703(99)70217-6. PubMed: 10097224.
30. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, et al. (1999) Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 83: 1201-1205. doi:10.1016/S0002-9149(99)00059-4. PubMed: 10215284.
31. Lotze U, Heinke S, Fritzenwanger M, Krack A, Müller S, et al. (2002) Carvedilol inhibits platelet-derived growth factor-induced signal transduction in human cardiac fibroblasts. J Cardiovasc Pharmacol 39: 576-589. doi:10.1097/00005344-200204000-00014. PubMed: 11904532.
32. Li B, Liao YH, Cheng X, Ge H, Guo H, et al. (2006) Effects of carvedilol on cardiac cytokines expression and remodeling in rat with acute myocardial infarction. Int J Cardiol 111: 247-255. doi:10.1016/j.ijcard.2005.08.065. PubMed: 16310260.
33. Wong VY, Laping NJ, Nelson AH, Contino LC, Olson BA, et al. (2001) Renoprotective effects of carvedilol in hypertensive-stroke prone rats may involve inhibition of TGF beta expression. Br J Pharmacol 134: 977-984. doi:10.1038/sj.bjp.0704329. PubMed: 11682445.
34. Vaughan DE, Rouleau JL, Pfeffer MA, (1995) Role of the fibrinolytic system in preventing myocardial infarction. Eur Heart J 16 (Suppl K):: 31-36. doi:10.1093/eurheartj/16.suppl_I.31. PubMed: 8869133.
35. Lijnen PJ, van Pelt JF, Fagard RH, (2012) Stimulation of reactive oxygen species and collagen synthesis by angiotensin II in cardiac fibroblasts. Cardiovasc Ther 30: e1-e8. doi:10.1111/j.1755-5922.2010.00231.x. PubMed: 20626399.
36. Gao Fei, Vuokko L, Kinnula, Myllärniemi M, Oury TD, (2008) Extracellular Superoxide Dismutase in Pulmonary Fibrosis. Antioxid Redox Signal 10: 343-354. doi:10.1089/ars.2007.1908. PubMed: 17999630.
37. Zhu H, Fan GC, (2012) Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res 94: 284-292. doi:10.1093/cvr/cvr291. PubMed: 22038740.
38. Qin W, Chung AC, Huang XR, Meng XM, Hui DS, et al. (2011) TGF-β/Smad3 signaling promotes renal fibrosis by inhibiting miR-29. J Am Soc Nephrol 22: 1462-1474. doi:10.1681/ASN.2010121308. PubMed: 21784902.